New drug HU6 cuts liver fat but preserves muscle mass
HU6, an experimental oral therapy from Rivus Pharmaceuticals, safely and effectively reduced liver fat and led to fat-selective weight loss in adults with metabolic…
News
Better to have Kasai surgery before liver transplant for biliary atresia
For infants with biliary atresia, undergoing standard Kasai surgery — a procedure to restore the flow of the digestive fluid bile in the body…
All spots filled in trial testing Vir’s combo treatment for hepatitis D
Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…
Most recent liver stiffness test best predicts risk of PBC progression
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…
Novel gene mutation is likely cause of newborn’s rare liver disease
A novel mutation in the NR1H4Â gene was the likely cause of progressive familial intrahepatic cholestasis (PFIC) type 5 in a baby girl in Tunisia,…
Emerging forever chemical may drive fatty liver disease
Exposure to a human-made chemical called perfluoroheptanoic acid (PFHpA) may increase the risk and severity of fatty liver disease in adolescents with obesity, according…
Why Mexican children with Alagille lag behind in getting proper care
Children in Mexico living with the complex genetic disease Alagille syndrome have limited access to essential care, including confirmatory genetic testing at diagnosis and,…
Hepatitis D therapy RBD1016 wins orphan drug designation in EU
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…
This year, it’s ‘hope into action’ for PSC Awareness Day
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
2 simple nutrients may be effective new screening tool for ICP
A new study has identified two dietary nutrients, choline and dimethylglycine, as effective potential biomarkers for diagnosing and monitoring intrahepatic cholestasis of pregnancy (ICP).
Recent Posts
- Alagille made us constantly worry about child milestones
- New drug HU6 cuts liver fat but preserves muscle mass
- Better to have Kasai surgery before liver transplant for biliary atresia
- All spots filled in trial testing Vir’s combo treatment for hepatitis D
- Most recent liver stiffness test best predicts risk of PBC progression